IL1B and neoplasm: We argued that these secreted factors could be an independent prognostic factor for low recurrence-free survival (RSF) in IRISOE TNBC patients [54] and showed that Anakinra (the FDA-approved IL-1β inhibitor) alone or together with SB265610 the CXCR2 (the receptor for CXCL1) inhibitor significantly blocked MSC, TAM, and EC recruitment into IRISOE TNBC tumors, reduced the circulating levels of CCL2 and VEGF, tumor growth, and significantly improved mice overall survival.